Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.

Leukemia - 1 Sept 2018

Than Hein, Qiao Yi, Huang Xiaomeng, Yan Dongqing, Khorashad Jamshid S, Pomicter Anthony D, Kovacsovics Tibor J, Marth Gabor T, O'Hare Thomas, Deininger Michael W

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Clonal Evolution
Share to Decitabine
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exome Sequencing

Share to Genetic Heterogeneity

Share to Leukemia, Myelomonocytic, Chronic

Share to Models, Biological

Source

Open in PubMed Open full text

Identifiers

PMID: 29588547
DOI: 10.1038/s41375-018-0050-z
PMCID: PMC6128729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.PMID 29588547Read ↗

Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort studySemantic proximity Read ↗

Emerging drugs for the treatment of chronic myelomonocytic leukemia.Semantic proximity Read ↗

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.Semantic proximity Read ↗

Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read ↗

Immunological effects of hypomethylating agents.Semantic proximity Read ↗

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.Semantic proximity Read ↗

Clonal dynamics in chronic lymphocytic leukemia.Semantic proximity Read ↗

Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy.Semantic proximity Read ↗

Clonal evolution in chronic myelogenous leukemiaSemantic proximity Read ↗

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia PatientsSemantic proximity Read ↗

Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroupSemantic proximity Read ↗

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.